Sign Out
Since controlled human reproduction studies have not been done with corticosteroids, the use of DIPROSPAN Suspension during pregnancy or in women of child-bearing age requires that the possible benefits of the drug be weighed against potential hazards to mother and fetus. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy should be observed carefully for signs of hypoadrenalism.
Because of the potential for unwanted adverse effects from DIPROSPAN Suspension in nursing infants, a decision should be made whether to discontinue nursing or to discontinue therapy, taking into account the importance of the drug to the mother.
